Drotrecogin alfa (activated) for severe sepsis

Connecticut Medicine

Volumn 66, Issue 3, 2002, Pages 145-150

  Maglio, Dana ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO;

CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036208123     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
2. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
3. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C
4. Severe sepsis - A new treatment with both anticoagulant and antiinflammatory properties
5. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
6. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis
7. Treatment of patients with disseminated intravascular coagulation by protein C
8. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
9. Treatment of purpura fulminans in meningococcemia with protein C concentrate
10. Protein C in the treatment of coagulopathy in meningococcal disease
11. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans
12. Efficacy and safety of recombinant human activated protein c for severe sepsis
13. Recombinant human activated protein c, drotrecogin alfa (activated): A novel therapy for severe sepsis
14. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care